LAVAL, QC, Sept. 5, 2019 /CNW/ - Crescita Therapeutics
Inc. (TSX: CTX) and (OTC US: CRRTF) (Crescita or the Company), a
Canadian commercial dermatology company with manufacturing
capabilities and a portfolio of non-prescription skincare products
and prescription drug products for the treatment and care of skin
conditions, diseases and their symptoms, today announced that its
executive chairman, Dan Chicoine will be presenting at this
year's Fall Investor Summit on Monday,
September 16th at 1:00 p.m. eastern
time in New York City. Mr.
Chicoine accompanied by Ms. Linda Kisa, Crescita's director of
investor relations, will also be meeting with investors one-on-one
during the event.
The Fall Investor Summit will take place at the Essex House,
featuring 160 companies and over 1,000 institutional and retail
investors.
About Crescita Therapeutics Inc.
Crescita (TSX:
CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial
dermatology company with manufacturing capabilities and a portfolio
of non-prescription skincare products and prescription drug
products for the treatment and care of skin conditions and diseases
and their symptoms. Crescita owns multiple proprietary drug
delivery platforms that support the development of patented
formulations that can facilitate the delivery of active drugs into
or through the skin. Please visit
www.crescitatherapeutics.com for additional information.
About The Investor Summit
The Investor Summit
(formerly MicroCap Conference) is an exclusive, independent
conference dedicated to connecting small cap and microcap companies
with qualified investors.
To register as a presenting company: please contact Cassandra Miller
(cassandra@microcapconf.com)
To request complimentary investor registration: please visit our
website at www.microcapconf.com
FOR MORE INFORMATION
Please visit: www.microcapconf.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/crescita-therapeutics-inc-to-present-at-the-fall-investor-summit-on-september-16th-17th-in-new-york-city-300912188.html
SOURCE Crescita Therapeutics Inc.